DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Australia ONLY.

Information about the NUVAXOVIDTM▼ (SARS-CoV-2 rS [NVX-CoV2373]) SUSPENSION FOR INJECTION

This vaccine has approval in Australia for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older. An additional dose of NUVAXOVID (0.5 mL) may be administered intramuscularly at least 6 months after completion of the second dose of the primary series in adults 18 years of age and older and at least 5 months after completion of the second dose of the primary series with NUVAXOVID in adolescents 12 to 17 years of age (NUVAXOVID has provisional approval for this use in adolescents). The use of this vaccine should be in accordance with official recommendations.

Report an Adverse Event (AE)

To report adverse event contact the Therapeutic Goods Administration (TGA) via their adverse event reporting site www.tga.gov.au/reporting-adverse-events.

Alternatively, adverse events can be reported to Novavax Pharmacovigilance at +61 2 7202 1444 or via the Novavax Adverse Event Reporting Form.

Contact Us

Tel: +61 2 7202 1444
09:00 - 17:00
Monday - Friday